Editor’s Note: The following story originally ran on National Pain Report on 11/12/16. It should be noted that the legitimacy of the company, Cannabis Science, has been criticized in the past. https://www.google.com/#
The new pharmaceutical medications will be in the form of a transdermal patch that is a medicated adhesive patch placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
The company behind the patches, Cannabis Science, says the patches:
“Promote healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive which will be containing high potency cannabinoid (CBD) extract that slowly enters into the bloodstream and then penetrates the central nervous system of the patient delivering the pain relief sought.”
Cannabis Science’s CEO Mr. Raymond C. Dabney says, “The development of these two new pharmaceutical medicinal applications are just the tip of the iceberg for what we see as the future for Cannabis Science. While we strive to increase our land capacity for growth and facilities to produce our own product to supply our scientists with proprietary materials to make these formulations, we are also busy researching more potential needs for Cannabis related medical applications and developing the methods for delivery of these medications.”
CBD is the second major cannabinoid in marijuana after THC. It has anti-inflammatory and pain-relieving properties, but without the psychoactive effects THC brings.
“As more states nationwide legislate for the legalization of cannabis and cannabis-derived medications, we here at Cannabis Science are focused on developing pharmaceutical formulations and applications to supply the huge growing demand expected over the coming few years,” concludes, Mr. Dabney.
Fibromyalgia is estimated to affect 2%-8% of the population, while females are about twice as likely to suffer from the condition. People with fibromyalgia experience chronic widespread pain and a heightened pain response to pressure.
Peripheral neuropathy (PN) is damage to, or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerves affected.